{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:20:14Z","timestamp":1794540014529,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11136-021-02952-9","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T03:52:13Z","timestamp":1626234733000},"page":"733-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-5430","authenticated-orcid":false,"given":"Cuc Thi Thu","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Thi Thu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Scuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-4286","authenticated-orcid":false,"given":"Iolanda","family":"Grappasonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"2952_CR1","unstructured":"American Society of Clinical Oncology. (2014). Leukemia\u2013chronic myeloid\u2014CML\u2014review. Retrieved November 23, 2015, from http:\/\/www.cancer.net\/cancer-types\/leukemia-chronic-myeloid-cml\/view-all."},{"issue":"7","key":"2952_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini, C., Antolini, L., Mahon, F. X., Guilhot, F., Deininger, M., Fava, C., et al. (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Journal of the National Cancer Institute, 103(7), 553\u2013561. https:\/\/doi.org\/10.1093\/jnci\/djr060","journal-title":"Journal of the National Cancer Institute"},{"key":"2952_CR3","doi-asserted-by":"publisher","unstructured":"Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011). Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am, 25(5), 981\u2013995, v, doi:https:\/\/doi.org\/10.1016\/j.hoc.2011.09.004.","DOI":"10.1016\/j.hoc.2011.09.004"},{"issue":"6","key":"2952_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., et al. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122(6), 872\u2013884. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"11","key":"2952_CR5","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"DL DeRemer","year":"2008","unstructured":"DeRemer, D. L., Ustun, C., & Natarajan, K. (2008). Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics, 30(11), 1956\u20131975.","journal-title":"Clinical Therapeutics"},{"issue":"24","key":"2952_CR6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio, G., Kim, D.-W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., et al. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251\u20132259.","journal-title":"New England Journal of Medicine"},{"key":"2952_CR7","unstructured":"NIDA Health Consequences of Drug Misuse. Retrieved September 23, 2019, from, https:\/\/www.drugabuse.gov\/publications\/health-consequences-drug-misuse\/mental-health-effects."},{"key":"2952_CR8","unstructured":"Organization, W. H. WHOQOL: Measuring Quality of Life. https:\/\/www.who.int\/healthinfo\/survey\/whoqol-qualityoflife\/en\/. Accessed 23 Sep 2019."},{"issue":"10","key":"2952_CR9","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.31323","volume":"124","author":"F Efficace","year":"2018","unstructured":"Efficace, F., Castagnetti, F., Martino, B., & Breccia, M. (2018). Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer, 124(10), 2228\u20132237. https:\/\/doi.org\/10.1002\/cncr.31323","journal-title":"Cancer"},{"issue":"5","key":"2952_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjh.16145","volume":"187","author":"F Huguet","year":"2019","unstructured":"Huguet, F., Cayuela, J. M., Cambier, N., Carpentier, N., Tindel, M., Violet, I., et al. (2019). Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: A prospective observational study in daily clinical practice. British Journal of Haematology, 187(5), 615\u2013626. https:\/\/doi.org\/10.1111\/bjh.16145","journal-title":"British Journal of Haematology"},{"issue":"5","key":"2952_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","volume":"16","author":"JE Cortes","year":"2016","unstructured":"Cortes, J. E., Lipton, J. H., Miller, C. B., Busque, L., Akard, L. P., Pinilla-Ibarz, J., et al. (2016). Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH Study. Clinical Lymphoma, Myeloma & Leukemia, 16(5), 286\u2013296. https:\/\/doi.org\/10.1016\/j.clml.2016.02.002","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"2","key":"2952_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4274\/tjh.2016.0409","volume":"34","author":"MC Ugur","year":"2017","unstructured":"Ugur, M. C., Kutbay, Y. B., Ozer Kaya, O., & Ceylan, C. (2017). Assessment of Quality of Life of Chronic Myeloid Leukemia patients by using the EORTC QLQ-C30. Turkish Journal of Haematology, 34(2), 197\u2013199. https:\/\/doi.org\/10.4274\/tjh.2016.0409","journal-title":"Turkish Journal of Haematology"},{"issue":"5","key":"2952_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.clml.2017.01.001","volume":"17","author":"T Sacha","year":"2017","unstructured":"Sacha, T., Gora-Tybor, J., Wasak-Szulkowska, E., Kyrcz-Krzemien, S., Medras, E., Becht, R., et al. (2017). Quality of Life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second-line therapy: A multicenter prospective observational study. Clinical Lymphoma, Myeloma & Leukemia, 17(5), 283\u2013295. https:\/\/doi.org\/10.1016\/j.clml.2017.01.001","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"2952_CR14","unstructured":"ICD10Data.com. https:\/\/www.icd10data.com\/ICD10CM\/Codes\/C00-D49\/C81-C96\/C92-\/C92.10."},{"issue":"5","key":"2952_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"2952_CR16","first-page":"262","volume":"81","author":"K Zawisza","year":"2010","unstructured":"Zawisza, K., Tobiasz-Adamczyk, B., Nowak, W., Kulig, J., & Jedrys, J. (2010). Validity and reliability of the quality of life questionnaire (EORTC QLQ C30) and its breast cancer module (EORTC QLQ BR23). Ginekologia Polska, 81(4), 262\u2013267.","journal-title":"Ginekologia Polska"},{"key":"2952_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2147\/ppa.s78334","volume":"9","author":"S Shuleta-Qehaja","year":"2015","unstructured":"Shuleta-Qehaja, S., Sterjev, Z., & Shuturkova, L. (2015). Evaluation of reliability and validity of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, Albanian version) among breast cancer patients from Kosovo. Patient Preference and Adherence, 9, 459\u2013465. https:\/\/doi.org\/10.2147\/ppa.s78334","journal-title":"Patient Preference and Adherence"},{"issue":"1","key":"2952_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/ijc.1439","volume":"94","author":"M Kyriaki","year":"2001","unstructured":"Kyriaki, M., Eleni, T., Efi, P., Ourania, K., Vassilios, S., & Lambros, V. (2001). The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample. International Journal of Cancer, 94(1), 135\u2013139. https:\/\/doi.org\/10.1002\/ijc.1439","journal-title":"International Journal of Cancer"},{"issue":"1","key":"2952_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1359-6349(12)70023-X","volume":"10","author":"G Velikova","year":"2012","unstructured":"Velikova, G., Coens, C., Efficace, F., Greimel, E., Groenvold, M., Johnson, C., et al. (2012). Health-Related Quality of Life in EORTC clinical trials\u201430 years of progress from methodological developments to making a real impact on oncology practice. European Journal of Cancer Supplements, 10(1), 141\u2013149. https:\/\/doi.org\/10.1016\/S1359-6349(12)70023-X","journal-title":"European Journal of Cancer Supplements"},{"key":"2952_CR20","unstructured":"R Core Team. (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing."},{"key":"2952_CR21","unstructured":"Scott, N. W., Fayers, P., Aaronson, N. K., Bottomley, A., de Graeff, A., Groenvold, M., et al. (2008). EORTC QLQ-C30 reference values manual."},{"key":"2952_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-017-0172-4","author":"I Mosweu","year":"2017","unstructured":"Mosweu, I., Moss-Morris, R., Dennison, L., Chalder, T., & McCrone, P. (2017). Cost-effectiveness of nurse-delivered cognitive behavioural therapy (CBT) compared to supportive listening (SL) for adjustment to multiple sclerosis. Health Economics Review. https:\/\/doi.org\/10.1186\/s13561-017-0172-4","journal-title":"Health Economics Review"},{"issue":"1","key":"2952_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"F Efficace","year":"2016","unstructured":"Efficace, F., & Cannella, L. (2016). The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology. American Society of Hematology. Education Program, 2016(1), 170\u2013179. https:\/\/doi.org\/10.1182\/asheducation-2016.1.170","journal-title":"Hematology. American Society of Hematology. Education Program"},{"issue":"7","key":"2952_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace, F., Baccarani, M., Breccia, M., Cottone, F., Alimena, G., Deliliers, G. L., et al. (2013). Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia, 27(7), 1511\u20131519. https:\/\/doi.org\/10.1038\/leu.2013.51","journal-title":"Leukemia"},{"issue":"17","key":"2952_CR25","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., et al. (2011). Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood, 118(17), 4554\u20134560. https:\/\/doi.org\/10.1182\/blood-2011-04-347575","journal-title":"Blood"},{"issue":"1","key":"2952_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1185\/03007990802619425","volume":"25","author":"CA McHorney","year":"2009","unstructured":"McHorney, C. A. (2009). The Adherence Estimator: A brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Current Medical Research and Opinion, 25(1), 215\u2013238. https:\/\/doi.org\/10.1185\/03007990802619425","journal-title":"Current Medical Research and Opinion"},{"issue":"10","key":"2952_CR27","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1007\/s12325-016-0394-6","volume":"33","author":"N Pag\u00e8s-Puigdemont","year":"2016","unstructured":"Pag\u00e8s-Puigdemont, N., Mangues, M. A., Masip, M., Gabriele, G., Fern\u00e1ndez-Maldonado, L., Blancafort, S., et al. (2016). Patients\u2019 perspective of medication adherence in chronic conditions: A qualitative study. Advances in Therapy, 33(10), 1740\u20131754. https:\/\/doi.org\/10.1007\/s12325-016-0394-6","journal-title":"Advances in Therapy"},{"key":"2952_CR28","doi-asserted-by":"publisher","unstructured":"Cancer-related fatigue. Clinical practice guidelines in oncology (2003). Journal of the National Comprehensive Cancer Networks, 1(3), 308\u2013331. https:\/\/doi.org\/10.6004\/jnccn.2003.0029.","DOI":"10.6004\/jnccn.2003.0029"},{"issue":"8","key":"2952_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., et al. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine, 363(8), 733\u2013742. https:\/\/doi.org\/10.1056\/NEJMoa1000678","journal-title":"New England Journal of Medicine"},{"issue":"9930","key":"2952_CR30","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/s0140-6736(13)62416-2","volume":"383","author":"C Zimmermann","year":"2014","unstructured":"Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., et al. (2014). Early palliative care for patients with advanced cancer: A cluster-randomised controlled trial. Lancet, 383(9930), 1721\u20131730. https:\/\/doi.org\/10.1016\/s0140-6736(13)62416-2","journal-title":"Lancet"},{"issue":"1","key":"2952_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","volume":"89","author":"WY Au","year":"2009","unstructured":"Au, W. Y., Caguioa, P. B., Chuah, C., Hsu, S. C., Jootar, S., Kim, D.-W., et al. (2009). Chronic myeloid leukemia in Asia. International Journal of Hematology, 89(1), 14\u201323.","journal-title":"International Journal of Hematology"},{"issue":"2","key":"2952_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jiph.2019.12.006","volume":"13","author":"FH Algahtani","year":"2020","unstructured":"Algahtani, F. H., & Alqahtany, F. S. (2020). Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study. Journal of Infection and Public Health, 13(2), 295\u2013298. https:\/\/doi.org\/10.1016\/j.jiph.2019.12.006","journal-title":"Journal of Infection and Public Health"},{"issue":"2","key":"2952_CR33","first-page":"78","volume":"73","author":"JW Kuan","year":"2018","unstructured":"Kuan, J. W., & Melaine Michael, S. (2018). The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Medical Journal of Malaysia, 73(2), 78\u201385.","journal-title":"Medical Journal of Malaysia"},{"issue":"9","key":"2952_CR34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.bbmt.2014.05.001","volume":"20","author":"A El-Jawahri","year":"2014","unstructured":"El-Jawahri, A., Pidala, J., Inamoto, Y., Chai, X., Khera, N., Wood, W. A., et al. (2014). Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 20(9), 1341\u20131348. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.001","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"3","key":"2952_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1515\/raon-2017-0021","volume":"51","author":"V Velenik","year":"2017","unstructured":"Velenik, V., Secerov-Ermenc, A., But-Hadzic, J., & Zadnik, V. (2017). Health-related Quality of Life Assessed by the EORTC QLQ-C30 Questionnaire in the general Slovenian population. Radiology and Oncology, 51(3), 342\u2013350. https:\/\/doi.org\/10.1515\/raon-2017-0021","journal-title":"Radiology and Oncology"},{"issue":"18","key":"2952_CR36","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.ejca.2015.08.027","volume":"51","author":"C Quinten","year":"2015","unstructured":"Quinten, C., Coens, C., Ghislain, I., Zikos, E., Sprangers, M. A., Ringash, J., et al. (2015). The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. European Journal of Cancer, 51(18), 2808\u20132819. https:\/\/doi.org\/10.1016\/j.ejca.2015.08.027","journal-title":"European Journal of Cancer"},{"issue":"8","key":"2952_CR37","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s11136-014-0675-y","volume":"23","author":"T Juul","year":"2014","unstructured":"Juul, T., Petersen, M. A., Holzner, B., Laurberg, S., Christensen, P., & Gronvold, M. (2014). Danish population-based reference data for the EORTC QLQ-C30: Associations with gender, age and morbidity. Quality of Life Research, 23(8), 2183\u20132193. https:\/\/doi.org\/10.1007\/s11136-014-0675-y","journal-title":"Quality of Life Research"},{"issue":"3","key":"2952_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.21037\/jgo.2019.02.04","volume":"10","author":"D Laghousi","year":"2019","unstructured":"Laghousi, D., Jafari, E., Nikbakht, H., Nasiri, B., Shamshirgaran, M., & Aminisani, N. (2019). Gender differences in health-related quality of life among patients with colorectal cancer. Journal of Gastrointestinal Oncology, 10(3), 453\u2013461. https:\/\/doi.org\/10.21037\/jgo.2019.02.04","journal-title":"Journal of Gastrointestinal Oncology"},{"issue":"5","key":"2952_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/ageing\/aft078","volume":"42","author":"DK Moser","year":"2013","unstructured":"Moser, D. K., Heo, S., Lee, K. S., Hammash, M., Riegel, B., Lennie, T. A., et al. (2013). \u201cIt could be worse \u2026 lot\u2019s worse!\u201d Why health-related quality of life is better in older compared with younger individuals with heart failure. Age and Ageing, 42(5), 626\u2013632. https:\/\/doi.org\/10.1093\/ageing\/aft078","journal-title":"Age and Ageing"},{"key":"2952_CR40","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2147\/ppa.s100873","volume":"10","author":"JW Wang","year":"2016","unstructured":"Wang, J. W., Sun, L., Ding, N., Li, J., Gong, X. H., Chen, X. F., et al. (2016). The association between comorbidities and the quality of life among colorectal cancer survivors in the People\u2019s Republic of China. Patient Preference and Adherence, 10, 1071\u20131077. https:\/\/doi.org\/10.2147\/ppa.s100873","journal-title":"Patient Preference and Adherence"},{"issue":"1","key":"2952_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11136-015-1061-0","volume":"25","author":"MC Adriaanse","year":"2016","unstructured":"Adriaanse, M. C., Drewes, H. W., van der Heide, I., Struijs, J. N., & Baan, C. A. (2016). The impact of comorbid chronic conditions on quality of life in type 2 diabetes patients. Quality of Life Research, 25(1), 175\u2013182. https:\/\/doi.org\/10.1007\/s11136-015-1061-0","journal-title":"Quality of Life Research"},{"issue":"1","key":"2952_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhealeco.2009.10.003","volume":"29","author":"DM Cutler","year":"2010","unstructured":"Cutler, D. M., & Lleras-Muney, A. (2010). Understanding differences in health behaviors by education. Journal of Health Economics, 29(1), 1\u201328. https:\/\/doi.org\/10.1016\/j.jhealeco.2009.10.003","journal-title":"Journal of Health Economics"},{"issue":"2","key":"2952_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jhealeco.2004.09.008","volume":"24","author":"A Case","year":"2005","unstructured":"Case, A., Fertig, A., & Paxson, C. (2005). The lasting impact of childhood health and circumstance. Journal of Health Economics, 24(2), 365\u2013389. https:\/\/doi.org\/10.1016\/j.jhealeco.2004.09.008","journal-title":"Journal of Health Economics"},{"issue":"16","key":"2952_CR44","doi-asserted-by":"publisher","first-page":"10929","DOI":"10.1073\/pnas.162086599","volume":"99","author":"DP Goldman","year":"2002","unstructured":"Goldman, D. P., & Smith, J. P. (2002). Can patient self-management help explain the SES health gradient? Proceedings of the National Academy of Sciences of the United States of America, 99(16), 10929\u201310934. https:\/\/doi.org\/10.1073\/pnas.162086599","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"2952_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pec.2010.03.015","volume":"79","author":"G Lagger","year":"2010","unstructured":"Lagger, G., Pataky, Z., & Golay, A. (2010). Efficacy of therapeutic patient education in chronic diseases and obesity. Patient Education and Counseling, 79(3), 283\u2013286. https:\/\/doi.org\/10.1016\/j.pec.2010.03.015","journal-title":"Patient Education and Counseling"},{"issue":"3","key":"2952_CR46","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace, F., Baccarani, M., Breccia, M., Saussele, S., Abel, G., Caocci, G., et al. (2014). International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Quality of Life Research, 23(3), 825\u2013836. https:\/\/doi.org\/10.1007\/s11136-013-0523-5","journal-title":"Quality of Life Research"},{"key":"2952_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1838509","author":"F Efficace","year":"2020","unstructured":"Efficace, F., Iurlo, A., Patriarca, A., Stagno, F., Bee, P. C., Ector, G., et al. (2020). Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukaemia & Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2020.1838509","journal-title":"Leukaemia & Lymphoma"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-021-02952-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T15:33:43Z","timestamp":1647272023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-021-02952-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1007\/s11136-021-02952-9","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"11 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of financial interests or personal relationships to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}